AI Drug Discovery Is Not One Thing
AI drug discovery is not one breakthrough. It is a stack of tools for target discovery, molecule design, toxicity prediction, clinical trials, and repurposing — each with a different burden…
AI Drug Discovery Is Getting Its Market Map
The AI drug discovery market is projected to grow from $8.8 billion in 2026 to $114.4 billion by 2033. The bigger story is whether AI can turn better maps of…
The First Wave of AI-Designed Drugs Hits Human Trials: A 2026 Status Report on Insilico, Isomorphic, and Recursion
As of May 2026, more than 75 AI-discovered drugs are in human trials. Inside the Insilico IPF Phase 2 program, Isomorphic Labs partnerships with Novartis and Lilly, Recursion’s Phase 2…
Cracking the Undruggable Code: How Daraxonrasib Just Rewrote the Rules for Pancreatic Cancer Survival
A new KRAS-targeting oral drug called daraxonrasib has nearly doubled survival in metastatic pancreatic cancer, with median overall survival of 13.2 months versus 6.7 months on chemotherapy in the landmark…
Senolytics in 2026: How the Science of Killing Zombie Cells Reached Its First Human Proof of Concept
A decade of senolytic research is converging into something new. Inside the Mayo Clinic dasatinib quercetin work, the AFFIRM-LITE fisetin trial, Rubedo’s March 2026 Phase 1 readout of RLS-1496, and…
Lp(a) and Heart Disease 2026: The Genetic Risk Factor Statins Cannot Touch and the New Wave of Therapies That Could Change Cardiology
An estimated 1.4 billion people globally carry elevated lipoprotein(a), a genetically inherited cardiovascular risk factor that statins do not lower. Inside the biology of Lp(a), why the science went quiet…
How Adrian Woolfson Is Helping Medicine Move From Reading DNA to Writing It
Adrian Woolfson trained under a Nobel laureate at Cambridge, ran global oncology programs at the world’s largest pharmaceutical companies, and led research and development at Sangamo Therapeutics during the first…
The Undruggable 80 Percent: Why AI Is Cracking the Proteins Medicine Couldn’t Touch
For four decades, a single protein drove roughly a third of all human cancers, and nobody could build a drug against it. Here is why that story is finally changing,…
The Nobel Ensemble: Inside the Lab Trying to End Disease
Five Nobel laureates are quietly orbiting Isomorphic Labs, the Alphabet-backed company trying to use artificial intelligence to end the world’s deadliest diseases. What they are building would have been science…
The Cardiac Amyloidosis Revolution: How ATTR Therapies Are Rewriting Heart Failure Treatment in 2026
For decades, cardiac amyloidosis was a diagnosis cardiologists whispered and patients rarely heard. In 2026, tafamidis, acoramidis, RNA silencers, and a CRISPR gene editing therapy are transforming ATTR care and…
